Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
83652 trials found · Page 7 of 4183
-
One-Shot gene therapy trial aims to free patients from debilitating pain crises
Disease control TerminatedThe purpose of the study is to evaluate the efficacy and safety of CTX001 (exa-cel) in adolescent and adult participants with severe sickle cell disease (SCD), βS/βC genotype (HbSC).
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New 'Supercharged' immune cell therapy targets Tough-to-Treat melanoma
Disease control Not yet recruitingThe protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
Phase: PHASE2 • Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated Apr 06, 2026 14:15 UTC
-
Engineered 'Natural Killer' cells target tough blood cancers
Disease control Not yet recruitingTo determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
New pill aims to extend life for deadly brain cancer patients
Disease control Not yet recruitingThe purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.
Phase: PHASE1, PHASE2 • Sponsor: NeuGATE Theranostics • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
New immune therapy trial aims to control Tough-to-Treat blood cancer
Disease control Not yet recruitingThis phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before autologous stem cell transplant in treating patients with d…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC
-
New drug combo trial aims to shrink stomach tumors before surgery
Disease control Not yet recruitingExploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy
Phase: PHASE3 • Sponsor: Fujian Medical University • Aim: Disease control
Last updated Apr 19, 2026 08:29 UTC
-
Family Donors' immune cells tested to rescue kids from stubborn Post-Transplant viruses
Disease control Not yet recruitingPatients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.
Phase: PHASE3 • Sponsor: New York Medical College • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Scientists weaponize herpes virus to fight deadly childhood brain cancer
Disease control Not yet recruitingThe goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New hope for AML patients: trial tests gentler drug combo against harsh chemo
Disease control Not yet recruitingThis international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction plus a FLT3inhibitor (quizartinib or midostaurin) (co…
Phase: PHASE2, PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New brain implant fights deadly cancer recurrence
Disease control Not yet recruitingThis study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozol…
Phase: PHASE2, PHASE3 • Sponsor: Everfront Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
Scientists test 'Living Drug' to fight tough breast cancers
Disease control Not yet recruitingThis phase Ib study aims to assess the safety and feasibility of combination of chimeric receptor T cells with trastuzumab in patients with HER2+ solid tumors, with further expansion of study population in HER2+ metastatic breast cancer once safety has been established.
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Apr 19, 2026 08:30 UTC
-
New hope for kids with Tough-to-Treat blood cancers
Disease control Not yet recruitingHEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol E is a phase I/II trial evaluating the safety and efficacy of capivasertib + ven…
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New blood test could replace invasive lung procedure for TB diagnosis
Diagnosis Not yet recruitingTuberculosis (TB) remains a major global health challenge, affecting over 10 million people annually. Hong Kong carries an intermediate TB burden, with \~3,200 new cases reported yearly. Pulmonary TB (PTB), the most common form, presents diagnostic difficulties. Traditional metho…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Mar 30, 2026 14:32 UTC
-
Race to stop bleeding in kids: major trial tests lifesaving drug
Disease control Not yet recruitingTrauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and/or torso injuries. …
Phase: PHASE3 • Sponsor: Daniel Nishijima, MD, MAS • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Early trial tests 'Living Drug' for tough cancers
Disease control Not yet recruitingThe goal of this clinical trial is to learn if CBG131 works to treat advanced gastric cancer or pancreatic cancer in adults whose tumors are CLDN18.2-positive. It will also learn about the safety of CBG131 and find the best dose to use. The main questions it aims to answer are: …
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC
-
New drug trial offers hope for girls with devastating neurological disorder
Disease control Recruiting nowPrimary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and wom…
Phase: PHASE3 • Sponsor: Biomed Industries, Inc. • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
Double-Duty treatment: new drug trial aims to boost gene therapy for baby muscle disease
Disease control Not yet recruitingIn this study, researchers will learn more about the safety and effects of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have already been treated with onasemnogene abeparvovec (OA) after being diagnosed with…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
Groundbreaking cell therapy trial launches for patients with aggressive blood cancers
Disease control Not yet recruitingThis is a hybrid type two study, with two simultaneous development phases. Phase A involves developing a public-private partnership to create the conditions for implementing CAR-T cell therapies in Colombia. Phase B will be a single-arm, non-randomized pilot clinical trial in pat…
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
Personal stem cells tested against rare brain disease
Disease control Not yet recruitingThis study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate funct…
Phase: PHASE2 • Sponsor: Biocells Medical • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Old blood pressure pill could be first to slow Parkinson's
Disease control Not yet recruitingTo assess target engagement of terazosin (TZ) at multiple doses (1 mg/day, 3 mg/day, and 5 mg/day) and to assess sustained target engagement over 6 months relative to placebo in patients with Parkinson's Disease (PD). Target engagement will be measured using a whole blood lumines…
Phase: PHASE1, PHASE2 • Sponsor: Nandakumar Narayanan • Aim: Disease control
Last updated Feb 19, 2026 14:38 UTC